Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humans

被引:26
作者
Glaeser, H
Drescher, S
Hofmann, U
Heinkele, G
Somogyi, AA
Eichelbaum, M
Fromm, MF
机构
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany
[2] Univ Adelaide, Dept Clin & Expt Pharmacol, Adelaide, SA, Australia
关键词
D O I
10.1016/j.clpt.2004.04.013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Aims. In humans gut wall metabolism can be quantitatively as important as hepatic drug metabolism in limiting the systemic exposure to drugs after oral administration. However, it has been proposed that the role of gut wall metabolism might be overemphasized, because high luminal drug concentrations would lead to a saturation of gut wall metabolism. Therefore we investigated the impact of concentration and rate of intraluminal drug delivery on absorption (F-abs.) and gastrointestinal extraction (E,,) of a luminally administered cytochrome P450 (CYP) 3A4 substrate (verapamil) using a multilumen perfusion catheter in combination with a stable isotope technique. Methods: Two 20-cm-long, adjacent jejunal segments were isolated with the multilumen perfusion catheter in 7 subjects. In this study 80 mg of unlabeled verapamil (d(0)-verapamil(15 min)) was infused into one segment over a 15-minute period, 80 mg of 3-fold deuterated verapamil (d(3)-verapamil(240) (min)) was administered over a 240-minute period into the other segment, and simultaneously, 5 mg of 7-fold deuterated verapamil (d(7)-verapamil) was injected intravenously over a 15-minute period. Results: The rate of intraluminal drug delivery had only a modest effect on bioavailability of the verapamil isotopes (after correction for F-abs) (F/F(abs)d(3)-verapamil(240 min) versus d(0)-verapamil(15 min), 0.24 +/- 0.10 versus 0.20 +/- 0.09; P < .05). Accordingly, the E-Gr value for d(3)-verapamil(240 min) was 0.50 +/- 0.18 compared with 0.59 +/- 0.14 for d(0)-verapamil(15 min). (P < .05). In vivo, E-GI(d(0)-verapamil(15 min)) correlated strongly with E-GI(d(3)-verapamil(240 min)) (r = 0.94, P < .005). Moreover, intrinsic clearance of CY-p3A4-mediated verapamil metabolism in homogenates of simultaneously collected shed enterocytes correlated with in vivo E-GI of d(0)-verapamil(15 min)/d(3)-verapamil(240 min) (v = 0.62, P = .03). Conclusions. Substantial gut wall metabolism of verapamil occurs in humans and can be predicted from ex vivo data by use of shed enterocytes. The different intraluminal concentrations and rates of intraluminal drug delivery did not lead to a pronounced saturation of intestinal drug metabolism.
引用
收藏
页码:230 / 238
页数:9
相关论文
共 30 条
[1]   PHARMACOKINETICS OF VERAPAMIL AND NORVERAPAMIL ENANTIOMERS AFTER ADMINISTRATION OF IMMEDIATE AND CONTROLLED-RELEASE FORMULATIONS TO HUMANS - EVIDENCE SUGGESTING INPUT-RATE DETERMINED STEREOSELECTIVITY [J].
BHATTI, MM ;
LEWANCZUK, RZ ;
PASUTTO, FM ;
FOSTER, RT .
JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (11) :1076-1082
[2]  
Busse D, 1995, N-S ARCH PHARMACOL, V353, P116
[3]   P-glycoprotein-mediated intestinal and biliary digoxin transport in humans [J].
Drescher, S ;
Glaeser, H ;
Mürdter, T ;
Hitzl, M ;
Eichelbaum, M ;
Fromm, MF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (03) :223-231
[4]  
EICHELBAUM M, 1982, ARZNEIMITTEL-FORSCH, V32-1, P575
[5]   SUPERIORITY OF STABLE ISOTOPE TECHNIQUES IN THE ASSESSMENT OF THE BIOAVAILABILITY OF DRUGS UNDERGOING EXTENSIVE 1ST PASS ELIMINATION - STUDIES OF THE RELATIVE BIOAVAILABILITY OF VERAPAMIL TABLETS [J].
EICHELBAUM, M ;
DENGLER, HJ ;
SOMOGYI, A ;
VONUNRUH, GE .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 19 (02) :127-131
[6]  
FUHR U, 1992, EUR J CLIN PHARMACOL, V42, P463
[7]   Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters [J].
Glaeser, H ;
Drescher, S ;
van der Kuip, H ;
Behrens, C ;
Geick, A ;
Burk, O ;
Dent, J ;
Somogyi, A ;
von Richter, O ;
Griese, EU ;
Eichelbaum, M ;
Fromm, MF .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (03) :131-140
[8]   Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans [J].
Gramatte, T ;
Oertel, R ;
Terhaag, B ;
Kirch, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (05) :541-549
[9]   PHARMACODYNAMIC PROFILE OF VERAPAMIL IN RELATION TO ABSOLUTE BIOAVAILABILITY - INVESTIGATIONS WITH A CONVENTIONAL AND A CONTROLLED-RELEASE FORMULATION [J].
HARDER, S ;
THURMANN, P ;
SIEWERT, M ;
BLUME, H ;
HUBER, T ;
RIETBROCK, N .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 17 (02) :207-212
[10]   COMPARATIVE BIOAVAILABILITY OF VERAPAMIL FROM RAPIDLY ABSORBED AND SLOW RELEASE PREPARATIONS [J].
JANKOWSKI, A ;
MARZEC, A ;
LAMPARCZYK, H .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1992, 10 (10-12) :1101-1103